Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 9;388(6):565-567.
doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11.

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

Ai-Ris Y Collier  1 , Jessica Miller  1 , Nicole P Hachmann  1 , Katherine McMahan  1 , Jinyan Liu  1 , Esther A Bondzie  1 , Lydia Gallup  1 , Marjorie Rowe  1 , Eleanor Schonberg  1 , Siline Thai  1 , Julia Barrett  1 , Erica N Borducchi  1 , Emily Bouffard  1 , Catherine Jacob-Dolan  1 , Camille R Mazurek  1 , Audrey Mutoni  1 , Olivia Powers  1 , Michaela Sciacca  1 , Nehalee Surve  1 , Haley VanWyk  1 , Cindy Wu  1 , Dan H Barouch  1
Affiliations

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

Ai-Ris Y Collier et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralizing Antibody and T-Cell Responses after Monovalent or Bivalent mRNA Boosting.
Shown are the results of luciferase-based pseudovirus neutralization assays among participants who received booster doses of either monovalent (Panel A) or bivalent (Panel B) mRNA vaccines. Also shown are spike-specific CD8+ T-cell responses on intracellular cytokine staining assays among participants who received booster doses of either monovalent (Panel C) or bivalent (Panel D) mRNA vaccines, along with corresponding CD4+ T-cell responses with the two types of vaccines (Panels E and F). Responses were measured against the ancestral strain of SARS-CoV-2 (WA1/2020) and against omicron sublineages BA.1, BA.2, and BA.5. Red horizontal bars indicate median values, as shown above the data points. The values above the brackets are the numerical factor differences in the response against the BA.5 variant after boosting as compared with the response before boosting (upper brackets) and the factor differences after boosting for the response against the ancestral strain as compared with the response against the BA.5 sublineage (lower brackets).
See this image and copyright information in PMC

Update of

References

    1. Lin D-Y, Gu Y, Xu Y, et al. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022;328:1415-1426. - PMC - PubMed
    1. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. N Engl J Med 2022;387:1332-1333. - PMC - PubMed
    1. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86-88. - PMC - PubMed
    1. Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med 2022;387:1279-1291. - PMC - PubMed
    1. Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (omicron) depends on previous SARS-CoV-2 exposure. Science 2022;377(6603):eabq1841-eabq1841. - PMC - PubMed

Publication types

Supplementary concepts